All Work Published on Regulation, Policy, Governance
Russ Altman’s Testimony Before the U.S. Senate Committee on Health, Education, Labor, and Pensions
In this testimony presented to the U.S. Senate Committee on Health, Education, Labor, and Pensions hearing titled “AI’s Potential to Support Patients, Workers, Children, and Families,” Russ Altman highlights opportunities for congressional support to make AI applications for patient care and drug discovery stronger, safer, and human-centered.
In this testimony presented to the U.S. Senate Committee on Health, Education, Labor, and Pensions hearing titled “AI’s Potential to Support Patients, Workers, Children, and Families,” Russ Altman highlights opportunities for congressional support to make AI applications for patient care and drug discovery stronger, safer, and human-centered.
Transparency in AI is on the Decline
A new study shows the AI industry is withholding key information.
A new study shows the AI industry is withholding key information.
Developing mental health AI tools that improve care across different groups and contexts
In order to realize the potential of mental health AI applications to deliver improved care, a multipronged approach is needed, including representative AI datasets, research practices that reflect and anticipate potential sources of bias, stakeholder engagement, and equitable design practices.
In order to realize the potential of mental health AI applications to deliver improved care, a multipronged approach is needed, including representative AI datasets, research practices that reflect and anticipate potential sources of bias, stakeholder engagement, and equitable design practices.
Michelle M. Mello's Testimony Before the U.S. House Committee on Energy and Commerce Health Subcommittee
In this testimony presented to the U.S. House Committee on Energy and Commerce’s Subcommittee on Health hearing titled “Examining Opportunities to Advance American Health Care through the Use of Artificial Intelligence Technologies,” Michelle M. Mello calls for policy changes that will promote effective integration of AI tools into healthcare by strengthening trust.
In this testimony presented to the U.S. House Committee on Energy and Commerce’s Subcommittee on Health hearing titled “Examining Opportunities to Advance American Health Care through the Use of Artificial Intelligence Technologies,” Michelle M. Mello calls for policy changes that will promote effective integration of AI tools into healthcare by strengthening trust.
“It connects back to my fear that the people with the fewest resources will be most affected by the downsides of AI,” says HAI Policy Fellow Riana Pfefferkorn in response to a viral AI-generated deepfake video.
“It connects back to my fear that the people with the fewest resources will be most affected by the downsides of AI,” says HAI Policy Fellow Riana Pfefferkorn in response to a viral AI-generated deepfake video.
Ethical Obligations to Inform Patients About Use of AI Tools
Permeation of artificial intelligence (AI) tools into health care tests traditional understandings of what patients should be told about their care. Despite the general importance of informed consent, decision support tools (eg, automatic electrocardiogram readers, rule-based risk classifiers, and UpToDate summaries) are not usually discussed with patients even though they affect treatment decisions. Should AI tools be treated similarly? The legal doctrine of informed consent requires disclosing information that is material to a reasonable patient’s decision to accept a health care service, and evidence suggests that many patients would think differently about care if they knew it was guided by AI. In recent surveys, 60% of US adults said they would be uncomfortable with their physician relying on AI,1 70% to 80% had low expectations AI would improve important aspects of their care,2 only one-third trusted health care systems to use AI responsibly,3 and 63% said it was very true that they would want to be notified about use of AI in their care.
Permeation of artificial intelligence (AI) tools into health care tests traditional understandings of what patients should be told about their care. Despite the general importance of informed consent, decision support tools (eg, automatic electrocardiogram readers, rule-based risk classifiers, and UpToDate summaries) are not usually discussed with patients even though they affect treatment decisions. Should AI tools be treated similarly? The legal doctrine of informed consent requires disclosing information that is material to a reasonable patient’s decision to accept a health care service, and evidence suggests that many patients would think differently about care if they knew it was guided by AI. In recent surveys, 60% of US adults said they would be uncomfortable with their physician relying on AI,1 70% to 80% had low expectations AI would improve important aspects of their care,2 only one-third trusted health care systems to use AI responsibly,3 and 63% said it was very true that they would want to be notified about use of AI in their care.